as 10-07-2025 10:07am EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | BERKELEY HEIGHTS |
Market Cap: | 865.2M | IPO Year: | 2010 |
Target Price: | $17.57 | AVG Volume (30 days): | 2.9M |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.79 | EPS Growth: | N/A |
52 Week Low/High: | $5.60 - $17.43 | Next Earning Date: | 10-29-2025 |
Revenue: | $121,484,498 | Revenue Growth: | 14970.29% |
Revenue Growth (this year): | 446.49% | Revenue Growth (next year): | 59.96% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
DUNTON ALAN W | CRMD | Director | Sep 12 '25 | Sell | $13.13 | 10,000 | $131,300.00 | 40,250 | |
Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 11 '25 | Sell | $13.08 | 41,121 | $537,862.68 | 176,990 | |
Zelnick Kaufman Beth | CRMD | Chief Legal Officer | Sep 9 '25 | Sell | $13.12 | 50,000 | $670,264.00 | 180,818 | |
Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 9 '25 | Sell | $13.51 | 12,876 | $173,954.76 | 176,990 |
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Zacks
15 days ago
Zacks
15 days ago
Zacks
25 days ago
Zacks
a month ago
Zacks
a month ago
Zacks
a month ago
Barchart
3 months ago
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.